Treatment of 5/6 nephrectomy rats with sulodexide： a novel therapy for chronic renal failure  

作　　者：Ping LI Lin-lin MA Ru-juan XIE Yuan-sheng XIE Ri-bao WEI Min YIN Jian-zhong WANG Xiang-mei CHEN 

机构地区：[1]State Key Laboratory of Kidney Disease(Chinese PLA General Hospital,2011DAVO0088),Beijing 100853,China [2]Harbin Medical University First Clinical Medical College,Department of Nephrology,Harbin 150001,China

出　　处：《Acta Pharmacologica Sinica》2012年第5期644-651,共8页中国药理学报（英文版）

摘　　要：Aim： Sulodexide, a glycosaminoglycan, could reduce albuminuria in diabetic patients. The aim of this study was to determine whether sulodexide could be used to treat chronic kidney failure in rats. Methods： Sixty Wistar rats undergone 5/6 nephrectomy, then were randomly divided into 4 groups： the model group, sulodexide group （sulodexide 5 mg/kg per day, im）, irbesartan group irbesartan （20 mg/kg per day, ig） and sulodexide plus irbesartan group. Another 12 rats were enrolled into the sham operation group. After the treatments for 4, 8 and 12 weeks, urinary protein and serum creatinine levels were measured. After 12 weeks, serum cholesterin and triglycerides levels were measured, and the degrees of glomerular sclerosis and renal tubulointerstitial fibrosis were scored. The expression of aminopeptidase P （JG-12） in the renal tissue was examined using immunohistochemical staining. The renal expressions of endothelial nitric oxide synthase （eNOS） and tissue type plasminogen activator （tPA） were detected with RT-PCR and Western blot. Results： Proteinuria was markedly attenuated in the sulodexide-treated groups. After 4 and 8 weeks only the sulodexide-treated groups showed significant reduction in serum creatinine; while after 12 weeks all the three treatment groups showed significant reduc- tion in serum creatinine. Furthermore, all the three treatment groups showed significant reduction in the scores of glomerular sclero- sis and tubulointerstitial fibrosis. The glomerular expression of JG-12 was increased in both the sulodexide group and the sulodexide plus irbesartan group, but not in the irbesartan group. The eNOS mRNA and protein expression was decreased and the tPA mRNA and protein expression was significantly increased in the model group compared with Sham group. Sulodexide, irbesartan, and their combination reversed the decrease of eNOS expression but increased the tPA expression much more compared with model group. Conclusion： Sulodexide was similar to irbesartan that can decreaAim： Sulodexide, a glycosaminoglycan, could reduce albuminuria in diabetic patients. The aim of this study was to determine whether sulodexide could be used to treat chronic kidney failure in rats. Methods： Sixty Wistar rats undergone 5/6 nephrectomy, then were randomly divided into 4 groups： the model group, sulodexide group （sulodexide 5 mg/kg per day, im）, irbesartan group irbesartan （20 mg/kg per day, ig） and sulodexide plus irbesartan group. Another 12 rats were enrolled into the sham operation group. After the treatments for 4, 8 and 12 weeks, urinary protein and serum creatinine levels were measured. After 12 weeks, serum cholesterin and triglycerides levels were measured, and the degrees of glomerular sclerosis and renal tubulointerstitial fibrosis were scored. The expression of aminopeptidase P （JG-12） in the renal tissue was examined using immunohistochemical staining. The renal expressions of endothelial nitric oxide synthase （eNOS） and tissue type plasminogen activator （tPA） were detected with RT-PCR and Western blot. Results： Proteinuria was markedly attenuated in the sulodexide-treated groups. After 4 and 8 weeks only the sulodexide-treated groups showed significant reduction in serum creatinine; while after 12 weeks all the three treatment groups showed significant reduc- tion in serum creatinine. Furthermore, all the three treatment groups showed significant reduction in the scores of glomerular sclero- sis and tubulointerstitial fibrosis. The glomerular expression of JG-12 was increased in both the sulodexide group and the sulodexide plus irbesartan group, but not in the irbesartan group. The eNOS mRNA and protein expression was decreased and the tPA mRNA and protein expression was significantly increased in the model group compared with Sham group. Sulodexide, irbesartan, and their combination reversed the decrease of eNOS expression but increased the tPA expression much more compared with model group. Conclusion： Sulodexide was similar to irbesartan that can decrea

关 键 词：chronic renal failure 5/6 nephrectomy SULODEXIDE IRBESARTAN endothelial nitric oxide synthase （eNOS） tissue type plasminogen activator （tPA） aminopeptidase P（JG-12） vascular endothelium 

分 类 号：Q959.837[生物学—动物学] S277.525[农业科学—农业水土工程]